Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC
More than half of Korean biopharma firms view R&D investments as assets.
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
Oscotec shares rebound on launch of US clinical trial
Oscotec wins exception policy for continued R&D for new drugs
Oscotec`s acute leukemia treatment wins orphan drug status from FDA
Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money
Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease
Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease
Other news to note for March 2, 2021
Profiles of Four New Stock-Billionaires
Yuhan to start phase-3 trial on lung cancer drug Lazertinib